May, 02 2016, 02:30pm EDT

Leaked TTIP Documents: Threats to Regulatory Protections
Statement of Robert Weissman, President, Public Citizen
WASHINGTON
Today, Greenpeace Netherlands leaked negotiating texts of the Transatlantic Trade and Investment Partnership (TTIP) agreement, the proposed trade deal between the United States and Europe. The leaks include 13 of 17 consolidated texts, as well as a European Union memorandum on the negotiating state of play. This statement provides a preliminary analysis of one of the leaked chapters, Regulatory Cooperation.
Statement of Robert Weissman, President, Public Citizen
Europe, beware. The leaked TTIP text confirms that the United States is trying to export its failed regulatory model. If the United States succeeds in its project, Big Business will gain enormous power to block, slow, undermine and repeal European regulations.
The leaked text makes clear that there are serious issues requiring analysis in particular sectors, but also that the Regulatory Cooperation chapter poses a major threat to health, safety, environmental, labor, consumer, civil and political rights, and other regulatory protections. The U.S. proposals in the Regulatory Cooperation chapter seek to export many of the worst features of U.S. rulemaking.
There is a lot to recommend about the U.S. regulatory process in theory, but in practice, the U.S. rulemaking process now evidences a massive tilt to favor the interests of regulated industries. It is far too slow; regulators are bogged down in seemingly endless analytic requirements that are themselves biased to favor the interests of regulated parties. Its veneration of "cost-benefit analysis" provides a pseudo-scientific cloak to industry's apocalyptic claims about the costs of the next regulation and operates at loggerheads with application of the precautionary principle.
In the days ahead, Public Citizen will issue a more detailed analysis of the draft Regulatory Cooperation chapter. These are among our top line concerns from the U.S. proposals in that chapter:
- Regulatory Delay - Paralysis by Analysis: Article X.13 would require parties to provide detailed and expansive justifications for their decision to issue a regulation, including consideration of regulatory alternatives. This is an inherently unequal obligation, because there is no burden to provide justification for doing nothing. In practice, the need to provide detailed justification for issuing a rule dramatically slows U.S. rulemaking.
- Corporate-Biased Cost Benefit Analysis: Article X.13.1.c would require parties to conduct detailed cost-benefit studies of regulations and regulatory alternatives. It is important to understand that the U.S. understanding of the phrase "anticipated costs and benefits" is fundamentally different than the European conception of regulatory impact assessment. In the United States, cost-benefit analysis is an extremely technical concept involving extensive data collection and elaborate modeling, and it is generally understood to be a near-absolute decision-making criterion. Its highly technical nature obscures the fact that cost estimates frequently rely on regulated industry-provided data and are excessive, and that non-quantifiable or indirect benefits are frequently not captured.
- One-Sided Analytic Requirements: Article X.13.2 would require parties to assess the impact of regulations on small businesses, a formal assessment under U.S. in certain circumstances that imposes extensive delay. It is also a one-sided required analysis, both under U.S. law and the U.S. TTIP proposal, because the specially required analysis looks to burdens ("adverse economic impacts" in the TTIP proposal) but not pro-competitive or other benefits to small business.
- Look Back, Not Forward: Article X.16 would require parties to undertake retrospective reviews of regulations. This is, again, an inherently uneven process, because the instruction is to search for rules to revise or repeal, not for regulatory shortcomings or gaps requiring new initiatives. In practice in the United States, the obligation to undertake regulatory reviews demands valuable time and resources from agencies, and interferes with their ability to conduct forward-looking activity.
- Trade Over the Public Interest: Article X.9 would impose a requirement for parties to consider trade effects of proposed regulations, and implicitly to justify any detrimental effects on trade. This is admittedly a soft requirement, but is notable inserting purely commercial considerations into regulatory decision-making and should be viewed as precursor to more robust demands in this area to follow.
Taken in their entirety, the U.S. Regulatory Cooperation proposals are affirmatively hostile to the precautionary principle. The precautionary principle counsels taking protective action in the face of uncertainty. The U.S. cost-benefit standards, demands for consideration of alternative regulatory approaches, and expansive analytic requirements also counsel for inaction in the face of uncertainty. Moreover, U.S.-style cost-benefit analysis places a premium on industry-provided cost estimates while effectively discounting benefits from action to prevent possible harm.
There is no need to overstate this tension; it is in fact possible to take precautionary action in a cost-benefit framework, as the United States sometimes does - but it is also the case that U.S.-style cost benefit is generally discordant with precautionary approaches.
The U.S. proposal notably does not include a requirement for judicial review of regulatory impact analytic requirements. This feature is central to the U.S. rulemaking process, but U.S. negotiators have recognized its incompatibility with European institutional arrangements.
It remains to be seen how a regulatory cooperation chapter will intersect with the investment chapter. But irrespective of the intersection with the investment chapter, Europeans should be aware that, if the U.S. Regulatory Cooperation proposals are accepted and TTIP is approved, it is only a matter of time before the United States and U.S. corporations begin advocating judicial review of European compliance with the provisions of the Regulatory Cooperation chapter.
Judicial review is an inherent part of the logic of the U.S. system, and there is no doubt that U.S. corporate interests will insist that judicial review is required to enforce the terms of the Regulatory Cooperation chapter.
Public Citizen is a nonprofit consumer advocacy organization that champions the public interest in the halls of power. We defend democracy, resist corporate power and work to ensure that government works for the people - not for big corporations. Founded in 1971, we now have 500,000 members and supporters throughout the country.
(202) 588-1000LATEST NEWS
Sanders Gets GOP Leader to Agree to Work On Medicare Covering Dental, Hearing, and Vision
The exchange on the Senate floor came after the Finance Committee chair blocked passage of the Vermont Independent's bill.
Mar 11, 2025
U.S. Senate Finance Committee Chair Mike Crapo on Tuesday blocked passage of Sen. Bernie Sanders' legislation to expand Medicare to cover dental, hearing, and vision care for tens of millions of American seniors, but the bill's sponsor got the panel leader to publicly agree to further discuss the issue.
Sanders (I-Vt.) took to the Senate floor Tuesday afternoon to ask for unanimous consent to pass the Medicare Dental, Hearing, and Vision Expansion Act, which is spearheaded in the House of Representatives by Congressman Lloyd Doggett (D-Texas).
"In the richest country in the history of the world, it is unacceptable that millions of seniors are unable to read because they can't afford eyeglasses, can't have conversations with their grandchildren because they can't afford hearing aids, and have trouble eating because they can't afford dentures," Sanders said in a statement.
"That should not be happening in the United States of America in the year 2025," he continued. "The time is long overdue for Congress to expand Medicare to include comprehensive coverage for the dental, vision, and hearing care that our seniors desperately need."
After Crapo (R-Idaho) rose to stop the bill from advancing, he and Sanders had a brief exchange in which the Republican agreed to working on achieving the "outcome" of the federal healthcare program covering dental, vision, and hearing.
In Sanders' remarks on the Senate floor about his bill, he sounded the alarm about efforts by President Donald Trump, billionaire Elon Musk, and congressional Republicans to cut government healthcare programs and Social Security.
"Yeah, we have more nuclear weapons than any other country, we have more billionaires than any other country, but we also have one of the highest rates of senior poverty of any country on Earth. We might want to get our priorities right," said Sanders, who has long fought for achieving universal healthcare in the United States via his Medicare for All legislation.
"While my Republican colleagues would like to make massive cuts to Medicaid in order to provide more tax breaks to billionaires, some of us have a better idea," he said. "We think that it makes more sense to substantially improve the lives of our nation's seniors by expanding Medicare to cover dental, vision, and hearing benefits."
To pay for his expansion plan, Sanders calls for ensuring that Medicare pays no more for prescription drugs than the Department of Veterans Affairs and addressing the tens of billions of dollars that privately administered Medicare Advantage plans overcharge the federal government annually.
In a statement about the bill, Doggett highlighted that "this expanded care could help prevent cognitive impairment and dementia, worsened chronic disease, and imbalance leading to falls with deadly consequences. This is an essential step to fulfilling the original promise of Medicare—to assure dignity and health for all."
Welcoming their renewed push for Medicare expansion, Public Citizen healthcare advocate Eagan Kemp declared that "at the same time Trump and his cronies in Congress try to rip healthcare away from millions and push for further privatization of Medicare, Sen. Sanders and Rep. Doggett are showing what one of our top priorities in healthcare should be—improving traditional Medicare."
"The introduction of this legislation is an important step to ensure Medicare enrollees can access the care they need, and we hope that Congress will act quickly to pass these commonsense reforms," Kemp added. "Healthcare is a human right."
Earlier Tuesday, in anticipation of Crapo's committee holding a confirmation hearing for Dr. Mehmet Oz, the former television host Trump has nominated to lead the Centers for Medicare and Medicaid, Public Citizen released a research brief about the hundreds of millions of dollars Medicare Advantage companies have spent on lobbying.
"If Oz is confirmed as the CMS administrator," Kemp warned, "attacks on traditional Medicare are likely to move into overdrive."
Keep ReadingShow Less
Trump Lifts Ukraine Aid Pause After Kyiv Agrees to Cease-Fire Proposal
Ukraine's foreign minister called the endorsement a "step that proves Ukraine is ready to move forward on the path to a just end to the war."
Mar 11, 2025
The Trump administration said Tuesday that it would resume military aid to and intelligence-sharing with Ukraine after that country's leadership endorsed a U.S. proposal for a 30-day cease-fire in the war defending against Russia's three-year invasion and occupation.
The Washington Postreports that U.S., Ukrainian, and Saudi officials met for eight hours on Tuesday in Jeddah, Saudi Arabia. No Russian officials were present at the negotiations.
"We're going to tell them this is what's on the table. Ukraine is ready to stop shooting and start talking," U.S. Secretary of State Marco Rubio said after the meeting. "And now it'll be up to them to say yes or no. If they say no, then we'll unfortunately know what the impediment is to peace here."
Ukraine has agreed to a 30 day ceasefire. Incredible work by Trump team. Now if Russia agrees, Trump may have gotten cease fires in the Middle East and Europe in his first 60 days. Nobel Peace Prize worthy: pic.twitter.com/lYogXVP8wj
— Clay Travis (@ClayTravis) March 11, 2025
White House National Security Adviser Michael Waltz said following the talks that "the Ukrainian delegation today made something very clear, that they share President [Donald] Trump's vision for peace, they share his determination to end the fighting, to end the killing, to end the tragic meat grinder of people."
Ukrainian Foreign Minister Andrii Sybiha called his country's endorsement of the cease-fire proposal a "step that proves Ukraine is ready to move forward on the path to a just end to the war."
"Ukraine is not an obstacle to peace; it is a partner in its restoration," Sybiha added.
U.S. officials said the cease-fire proposal will now be sent to Russia for approval. It is unclear whether Russian President Vladimir Putin will accept the offer.
"The ball is now in their court," Rubio said of the Russians.
Buoyed by Western support but stretched thin and vastly outmanned and outgunned, Ukrainian forces have been struggling to repel Russia's invasion and hold Russian territory they seized in the Kursk region, with an eye toward potential future territorial exchanges.
On Tuesday, Ukrainian forces launched a massive drone attack on Moscow. Three people were reportedly killed and six others were injured when debris struck a meat processing facility.
Tuesday's development marked a dramatic turnaround from just two weeks ago, when Trump and Vice President JD Vance lambasted Ukrainian President Volodymyr Zelenskyy during a highly contentious White House meeting that was followed by a suspension of all U.S. military assistance and intelligence-sharing with Kyiv.
The U.S. has "provided $66.5 billion in military assistance since Russia launched its premeditated, unprovoked, and brutal full-scale invasion of Ukraine on February 24, 2022, and approximately $69.2 billion in military assistance since Russia's initial invasion of Ukraine in 2014," according to a State Department fact sheet dated March 4.
Keep ReadingShow Less
Watchdog Exposes Millions in Medicare Advantage Lobbying Ahead of Dr. Oz Hearing
"If Oz is confirmed as the CMS administrator, attacks on traditional Medicare are likely to move into overdrive," said one advocate, calling to strengthen the program, "not weaken it through further privatization."
Mar 11, 2025
The watchdog group Public Citizen on Tuesday released a research brief about the hundreds of millions of dollars Medicare Advantage companies have spent on lobbying ahead of a U.S. Senate confirmation hearing for Dr. Mehmet Oz.
Oz, a heart surgeon and former television host, is President Donald Trump's nominee to run the Centers for Medicare and Medicaid (CMS)—an agency in the U.S. Department of Health and Human Services, which is led by conspiracy theorist Robert F. Kennedy Jr.
Health experts and others have sounded the alarm about Oz since Trump announceded his nomination in November, with many opponents highlighting the doctor's investments in companies with direct CMS interests and his push to expand Medicare Advantage when he unsuccessfully ran as a Republican to represent Pennsylvania in the U.S. Senate in 2022.
Medicare Advantage is a type of CMS-approved health insurance plan from a private company that seniors can choose for medical coverage instead of government-administered Medicare. Critics often call it a "profit-seeking healthcare scam."
Public Citizen's brief points out that last year, "more than half of all seniors eligible for Medicare were enrolled" in these private plans that "cost taxpayers hundreds of billions of dollars and deliver inferior care compared to traditional Medicare."
"Since their inception in 2003, Medicare Advantage plans are estimated to have cost taxpayers more than $600 billion in overpayments," the document notes. "These overpayments are expected to grow to $1 trillion over the next decade."
"Just seven companies account for 84% of all Medicare Advantage enrollment," the brief continues. "While lobbying disclosures do not reveal how much is spent on a single issue, disclosures reveal that these seven companies spent more than $330 million combined lobbying on all issues over the last five years, according to data from OpenSecrets."
Those companies are UnitedHealthcare, Humana, Blue Cross Blue Shield, CVS Health, Kaiser, Centene, and Cigna.
Public Citizen found that in 2024, they collectively had 328 lobbyists targeting the federal government, with nearly 70% of them specifically working on Medicare Advantage. Blue Cross had the most lobbyists focused on such plans (99), followed by Humana (33) and UnitedHealth Group (27).
"If Oz is confirmed as the CMS administrator, attacks on traditional Medicare are likely to move into overdrive," Eagan Kemp, a healthcare policy advocate at Public Citizen, warned in a Tuesday statement. "We should strengthen Medicare by improving it and expanding access to it, not weaken it through further privatization."
The Senate Committee on Finance is set to consider Oz on Friday morning. Since Trump returned to the White House in January, the GOP-controlled chamber hasn't blocked any of his nominees.
Keep ReadingShow Less
Most Popular